Recently an association between hyperprolactinaemia and certain rheumatic diseases has been described suggesting that PRL may play a role in the pathogenesis of some autoimmune diseases.94 In addition, PRL seems to be an autocrine factor required for viability and proliferation of B lymphoma cells.5 Furthermore, it was recently proposed that hyperprolactinaemia observed in oestrogentreated mice may predispose to development of lymphoma in these animals. 6 Primary Sj6gren's syndrome (P-SS) is a chronic autoimmune disease characterised by exocrine glandular insufficiency secondary to lymphocytic and plasma cell infiltration. The spectrum of the disease extends from an organ specific autoimmune disease to a systemic involvement.7 Characteristically, patients with Sjogren's syndrome (SS) have an increased risk of developing lymphoma.'
To investigate an eventual association between hyperprolactinaemia and P-SS, we studied the basal levels of PRL (Radioimmunoassay, NIDDK reagents) in sera from 11 patients with P-SS. The clinical and laboratory characteristics of the patients and their PRL levels are summarised in table 1. Serum from 11 healthy individuals (6 women and 5 men, mean age 40 years) was obtained as controls. All blood samples were obtained at mid morning (always at the same time) and sera were stored frozen at -70°C until tested. None of the patients or controls were taking medication that could increase serum PRL levels (including oestrogen replacement therapy), or had unusual psychological distress that may be associated with increased levels of PRL. All patients had a normal sized sella turcica, normal visual fields, and normal fundoscopic examinations. However, the presence of a pituitary PRL-secreting microadenoma can not be excluded. None of the patients had chronic renal failure, or hypothyroidism.
Sera from five patients (45 5%) were found to have hyperprolactinaemia (PRL > 20 ng/ml). These preliminary data showed the presence of hyperprolactinaemia in a subset of P-SS patients. Although there were more females in the patient group all of them were postmenopausal women (without oestrogen replacement therapy), so that high PRL levels were not influenced by oestrogen. The exact cause of hyperprolactinaemia in this subset of P-SS patients needs further investigation. However, it could be a dysfunction of the neuroendocrine system with an imbalance between increased immunostimulatory PRL and decreased immunosuppressive cortisol as has been described in patients with RA.9 Another potential source of the hyperprolactinaemia found in these patients is the PRL released by lymphocytes. T and B lymphocytes may produce PRL-like proteins that are biologically active that function as autocrine growth factor for lymphoproliferation.10 Further studies, including a larger number of patients and serial determinations of the hormone to confirm these observations and to establish the exact role of PRL in P-SS, are needed. 
